VH 032 propargyl is used as a key intermediate in the synthesis of specific chemical compounds, particularly in pharmaceutical research. It aids in developing agents that target certain proteins involved in chronic diseases such as cancer. This compound plays a role in inhibiting the function of the VHL (von Hippel-Lindau) protein, allowing control of HIF (Hypoxia-Inducible Factor) protein levels, which is crucial for cellular response to hypoxia.

In drug development, it serves as a core molecule in designing targeted therapies, especially in the PROTACs (Proteolysis Targeting Chimeras) class, a novel technology that enables efficient degradation of aberrant or disease-causing proteins from cells.

Additionally, it is used in research laboratories to study intracellular signaling pathways and gene expression regulation related to cell growth and hypoxic conditions. The propargyl group facilitates bioorthogonal chemistry applications, such as click labeling for detection and pull-down assays.